CTX130 Trademark

Trademark Overview


On Monday, October 17, 2022, a trademark application was filed for CTX130 with the United States Patent and Trademark Office. The USPTO has given the CTX130 trademark a serial number of 97635360. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 2, 2024. This trademark is owned by CRISPR Therapeutics AG. The CTX130 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematologic malignancies; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of hematologic malignancies; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of hematologic malignancies
ctx130

General Information


Serial Number97635360
Word MarkCTX130
Filing DateMonday, October 17, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 27, 2024

Trademark Statements


Goods and ServicesCells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematologic malignancies; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy
Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of hematologic malignancies; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of hematologic malignancies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 20, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, October 20, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCRISPR Therapeutics AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressZUG V8 6300
CH

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressZUG V8 6300
CH

Trademark Events


Event DateEvent Description
Thursday, October 20, 2022NEW APPLICATION ENTERED
Thursday, October 20, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 31, 2023ASSIGNED TO EXAMINER
Tuesday, May 9, 2023NON-FINAL ACTION WRITTEN
Tuesday, May 9, 2023NON-FINAL ACTION E-MAILED
Tuesday, May 9, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 9, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 9, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 10, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 19, 2023ASSIGNED TO EXAMINER
Monday, October 2, 2023FINAL REFUSAL WRITTEN
Monday, October 2, 2023FINAL REFUSAL E-MAILED
Monday, October 2, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, December 22, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, December 22, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, December 22, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, December 22, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 23, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 27, 2024PUBLISHED FOR OPPOSITION
Monday, March 4, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 23, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED